Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Am J Physiol Lung Cell Mol Physiol
2015 Oct 01;3097:L687-99. doi: 10.1152/ajplung.00181.2015.
Show Gene links
Show Anatomy links
Murine and human CFTR exhibit different sensitivities to CFTR potentiators.
Cui G
,
McCarty NA
.
???displayArticle.abstract???
Development of therapeutic molecules with clinical efficacy as modulators of defective CFTR includes efforts to identify potentiators that can overcome or repair the gating defect in mutant CFTR channels. This has taken a great leap forward with the identification of the potentiator VX-770, now available to patients as "Kalydeco." Other small molecules with different chemical structure also are capable of potentiating the activity of either wild-type or mutant CFTR, suggesting that there are features of the protein that may be targeted to achieve stimulation of channel activity by structurally diverse compounds. However, neither the mechanisms by which these compounds potentiate mutant CFTR nor the site(s) where these compounds bind have been identified. This knowledge gap partly reflects the lack of appropriate experimental models to provide clues toward the identification of binding sites. Here, we have compared the channel behavior and response to novel and known potentiators of human CFTR (hCFTR) and murine (mCFTR) expressed in Xenopus oocytes. Both hCFTR and mCFTR were blocked by GlyH-101 from the extracellular side, but mCFTR activity was increased with GlyH-101 applied directly to the cytoplasmic side. Similarly, glibenclamide only exhibited a blocking effect on hCFTR but both blocked and potentiated mCFTR in excised membrane patches and in intact oocytes. The clinically used CFTR potentiator VX-770 transiently increased hCFTR by ∼13% but potentiated mCFTR significantly more strongly. Our results suggest that mCFTR pharmacological sensitivities differ from hCFTR, which will provide a useful tool for identifying the binding sites and mechanism for these potentiators.
Budriesi,
Cystic fibrosis: a new target for 4-Imidazo[2,1-b]thiazole-1,4-dihydropyridines.
2011, Pubmed
Budriesi,
Cystic fibrosis: a new target for 4-Imidazo[2,1-b]thiazole-1,4-dihydropyridines.
2011,
Pubmed
Caci,
Evidence for direct CFTR inhibition by CFTR(inh)-172 based on Arg347 mutagenesis.
2008,
Pubmed
Cotten,
Cystic fibrosis-associated mutations at arginine 347 alter the pore architecture of CFTR. Evidence for disruption of a salt bridge.
1999,
Pubmed
Cui,
Mutations at arginine 352 alter the pore architecture of CFTR.
2008,
Pubmed
,
Xenbase
Cui,
Differential contribution of TM6 and TM12 to the pore of CFTR identified by three sulfonylurea-based blockers.
2012,
Pubmed
,
Xenbase
Cui,
Three charged amino acids in extracellular loop 1 are involved in maintaining the outer pore architecture of CFTR.
2014,
Pubmed
,
Xenbase
Eckford,
Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner.
2012,
Pubmed
Gabriel,
Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model.
1994,
Pubmed
Gadsby,
The ABC protein turned chloride channel whose failure causes cystic fibrosis.
2006,
Pubmed
Galietta,
Identification of CFTR activators and inhibitors: chance or design?
2004,
Pubmed
Grove,
Mechanisms for rescue of correctable folding defects in CFTRDelta F508.
2009,
Pubmed
Guilbault,
Cystic fibrosis mouse models.
2007,
Pubmed
Jih,
Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle.
2013,
Pubmed
Lansdell,
Comparison of the gating behaviour of human and murine cystic fibrosis transmembrane conductance regulator Cl- channels expressed in mammalian cells.
1998,
Pubmed
Lansdell,
Regulation of murine cystic fibrosis transmembrane conductance regulator Cl- channels expressed in Chinese hamster ovary cells.
1998,
Pubmed
Levin,
Potential difference measurements of ocular surface Na+ absorption analyzed using an electrokinetic model.
2006,
Pubmed
McCarty,
Permeation through the CFTR chloride channel.
2000,
Pubmed
McCarty,
Identification of a region of strong discrimination in the pore of CFTR.
2001,
Pubmed
,
Xenbase
McDonough,
Novel pore-lining residues in CFTR that govern permeation and open-channel block.
1994,
Pubmed
Mense,
In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer.
2006,
Pubmed
,
Xenbase
Neuberger,
Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators.
2011,
Pubmed
Ostedgaard,
Processing and function of CFTR-DeltaF508 are species-dependent.
2007,
Pubmed
Penmatsa,
Clinical and molecular characterization of S1118F-CFTR.
2009,
Pubmed
Scott-Ward,
Chimeric constructs endow the human CFTR Cl- channel with the gating behavior of murine CFTR.
2007,
Pubmed
Sondo,
Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling.
2011,
Pubmed
Song,
Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models.
2004,
Pubmed
Stahl,
Divergent CFTR orthologs respond differently to the channel inhibitors CFTRinh-172, glibenclamide, and GlyH-101.
2012,
Pubmed
,
Xenbase
Sullivan,
Epithelial transport in polycystic kidney disease.
1998,
Pubmed
Van Goor,
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.
2009,
Pubmed
Van Goor,
Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function.
2014,
Pubmed
Venglarik,
Tolbutamide causes open channel blockade of cystic fibrosis transmembrane conductance regulator Cl- channels.
1996,
Pubmed
Walters,
Mechanism by which calcium phosphate coprecipitation enhances adenovirus-mediated gene transfer.
1999,
Pubmed
Wang,
Activating cystic fibrosis transmembrane conductance regulator channels with pore blocker analogs.
2005,
Pubmed
Wang,
ATP-independent CFTR channel gating and allosteric modulation by phosphorylation.
2010,
Pubmed
Wang,
An electrostatic interaction at the tetrahelix bundle promotes phosphorylation-dependent cystic fibrosis transmembrane conductance regulator (CFTR) channel opening.
2014,
Pubmed
Wilke,
Mouse models of cystic fibrosis: phenotypic analysis and research applications.
2011,
Pubmed
Yang,
Stabilization of ion selectivity filter by pore loop ion pairs in an inwardly rectifying potassium channel.
1997,
Pubmed
,
Xenbase
Yu,
Ivacaftor potentiation of multiple CFTR channels with gating mutations.
2012,
Pubmed
Zhang,
Time-dependent interactions of glibenclamide with CFTR: kinetically complex block of macroscopic currents.
2004,
Pubmed
,
Xenbase
Zhang,
State-dependent chemical reactivity of an engineered cysteine reveals conformational changes in the outer vestibule of the cystic fibrosis transmembrane conductance regulator.
2005,
Pubmed
Zhang,
Direct comparison of NPPB and DPC as probes of CFTR expressed in Xenopus oocytes.
2000,
Pubmed
,
Xenbase
